Sodium [2′-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-4′-(6- ethoxy-pyridin-3-yl)-6-methoxy-biphenyl-3-yl]-acetate (AM432): A potent, selective prostaglandin D2 receptor antagonist

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 3, 2011, Pages 1036-1040

  Stock, Nicholas ^a   Volkots, Deborah ^a   Stebbins, Karin ^a   Broadhead, Alex ^a   Stearns, Brian ^a   Roppe, Jeffrey ^a   Parr, Timothy ^a   Baccei, Christopher ^a   Bain, Gretchen ^a   Chapman, Charles ^a   Correa, Lucia ^a   Darlington, Janice ^a   King, Christopher ^a   Lee, Catherine ^a   Lorrain, Daniel S ^a   Prodanovich, Pat ^a   Santini, Angelina ^a   Evans, Jilly F ^a   Hutchinson, John H ^a   Prasit, Peppi ^a  

^a Amira Pharmaceuticals   (United States)

Author keywords

Antagonist; CRTH2; DP2 receptor; Prostaglandin D2

Indexed keywords

AM 432; PROSTAGLANDIN D2; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; SODIUM [2' [(CYCLOPROPANECARBONYLETHYLAMINO)METHYL] 4' (6 ETHOXYPYRIDIN 3 YL) 6 METHOXYBIPHENYL 3 YL]ACETATE; UNCLASSIFIED DRUG; (2' ((CYCLOPROPANECARBONYLETHYLAMINO)METHYL) 4' (6 ETHOXY PYRIDIN 3 YL) 6 METHOXYBIPHENYL 3 YL)ACETIC ACID; (2'-((CYCLOPROPANECARBONYLETHYLAMINO)METHYL)-4'-(6-ETHOXY-PYRIDIN-3-YL)-6-METHOXYBIPHENYL-3-YL)ACETIC ACID; IMMUNOGLOBULIN RECEPTOR; PHENYLACETIC ACID DERIVATIVE; PROSTAGLANDIN D2 RECEPTOR; PROSTAGLANDIN RECEPTOR; PYRIDINE DERIVATIVE;

ALLERGIC RHINITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CELL SHAPE; CHEMICAL MODIFICATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; DRUG ACTIVITY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; EOSINOPHIL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; ANIMAL; CHEMISTRY; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; INFLAMMATION; METABOLISM; ORAL DRUG ADMINISTRATION;

CANIS FAMILIARIS;

ADMINISTRATION, ORAL; ANIMALS; DISEASE MODELS, ANIMAL; DOGS; EOSINOPHILS; HUMANS; INFLAMMATION; MICE; PHENYLACETATES; PYRIDINES; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN;

EID: 78751649417     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.12.016     Document Type: Article

References (20)

1. R. Pettipher, T.T. Hansel, and R. Armer Nat. Rev. Drug Disc. 6 2007 313
2. E. Kostensis, and T. Ulven Trends Mol. Med. 12 2006 148
3. P. Norman Expert Opin. Invest. Drugs 19 2010 947
4. Scott, J. M.; Baccei, C.; Bain, G.; Broadhead, A.; Evans, J. F.; Fagan, P.; Hutchinson, J. H.; King, C.; Lorrain, D. S.; Lee, C.; Prasit, P.; Prodanovich, P.; Santini, A.; Stearns, B. A. Bioorg. Med. Chem. Lett. 2010, accepted for publication.
5. K.J. Stebbins, A.R. Broadhead, L.D. Correa, J.M. Scott, Y.P. Truong, B.A. Stearns, J.H. Hutchinson, P. Prasit, J.F. Evans, and D.S. Lorrain Eur. J. Pharmacol. 638 2010 142
6. 50) was determined. The binding assay was carried out both in the absence and presence of 0.2% human serum albumin (HSA) to evaluate the protein shift associated with the compounds.
7. 2 (50 nM final concentration) or vehicle was added from a 1 μM stock in PBS and incubations were continued for 5 min at 37 °C. The reactions were placed on ice and 250 μL of ice-cold 1:4 diluted Cytofix (BD Biosciences) in PBS immediately added. The reactions were transferred to FACS tubes and lysed with ammonium chloride lysing solution at room temperature for 15 min. Tubes were centrifuged and the cells washed once with 3 mL cold PBS before re-suspension in 200 μL of ice-cold 1:4 diluted Cytofix in PBS. Eosinophil shape change was analyzed on a FACS calibur by analyzing forward light scatter of the autofluorescent cells.
8. Carbamates are often irreversible inhibitors of various enzymes, see for example: J.P. Alexander, and B.F. Cravatt Chem. Biol. 12 2005 1179
9. G. Lin, G.-H. Chen, and H.-C. Ho Bioorg. Med. Chem. Lett. 8 1998 2747
10. L. Hosie, L.D. Sutton, and D.M. Quinn J. Biol. Chem. 262 1987 260
11. For a review on the Suzuki-Miyaura reaction, see: N. Miyaura, and A. Suzuki Chem. Rev. 95 1995 2457
12. hERG analysis performed by ChanTest corporation using a patch-clamp style assay.
13. R.M. Naclerio, H.L. Meier, A. Kagey-Sobotka, N.F. Adkinson Jr., D.A. Meyers, P.S. Norman, and L.M. Lichtenstein Am. Rev. Respir. Dis. 128 1983 597
14. T. Seibert, M. Depner, M. Kormann, N. Knopp, T. Illig, E. von Mutius, M. Kasbech, and L. Cameron J. Allergy Clin. Immunol. 121 2008 S81
15. H. Shirasaki, M. Kikuchi, E. Kanaizumi, and T. Himi Ann. Allergy Asthma Immunol. 102 2009 110
16. M. Nakaya, M. Dohi, K. Okunishi, K. Nakagome, R. Tanaka, M. Imamura, S. Baba, N. Takeuchi, K. Yamamoto, and K. Kaga Lab. Invest. 86 2006 917
17. R. Nomiya, M. Okano, T. Fujiwara, M. Maeda, Y. Kimura, K. Kino, M. Yokoyama, H. Hirai, K. Nagata, T. Hara, K. Nishizaki, and M. Nakamura J. Immunol. 180 2008 5680
18. Y. Shirashi, L.E. Burgess, K. Takeda, C. Eberhardt, D. Wright, A. Cook, C. Corrette, K. Hunt, C. Clark, G. Kim, K. Delisle, L. Hayter, J. Neale, D. Chantry, G. Doherty, and E.W. Gelfand Am. J. Respir. Crit. Care Med. 179 2009 A5718
19. K.J. Stebbins, A.R. Broadhead, C.S. Baccei, J.M. Scott, Y.P. Truong, H. Coate, N.S. Stock, A.M. Santini, P. Fagan, P. Prodanovich, G. Bain, B.A. Stearns, C.D. King, J.H. Hutchinson, P. Prasit, J.F. Evans, and D.S. Lorrain J. Pharmacol. Exp. Ther. 332 2010 764
20. Sargent, C.; Stinson, S.; Schmidt, J.; Dougall, I.; Bonnert, R.; Paine, S.; Saunders, M.; Foster, M. In Proceedings of the British Pharmacological Society 2009, 7th James Black Conference, www.pa2online.org.